Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double‐blind, placebo‐controlled, Phase I trial

Abstract Aim This Phase I study evaluated the safety and early efficacy of an aldosterone synthase inhibitor (BI 690517) in people with diabetes and albuminuric chronic kidney disease. Methods Double‐blind, placebo‐controlled study (NCT03165240) at 40 sites across Europe. Eligible participants estimated glomerular filtration rate ≥20 and <75 ml/min/1.73 m 2 ; urine albumin/creatinine ratio (UACR) ≥200 and <3500 mg/g were randomized 6:1 to receive once‐daily oral BI 690517 3, 10 or 40 mg, or eplerenone 25‐50 mg, or placebo, for 28 days. The primary endpoint was the proportion of participants with drug‐related adverse events (AEs). Secondary endpoints included changes from baseline in the UACR. Results Fifty‐eight participants were randomized and treated from 27 November 2017 to 16 April 2020 (BI 690517: 3 mg, n = 18; 10 mg, n = 13; 40 mg, n = 14; eplerenone, n = 4; placebo, n = 9) for 28 days. Eight (13.8%) participants experienced drug‐related AEs BI 690517: 3 mg (two of 18); 10 mg (four of 13); 40 mg (two of 14), most frequently constipation 10 mg (one of 13); 40 mg (one of 14) and hyperkalaemia 3 mg (one of 18); 10 mg (one of 13). Most AEs were mild to moderate; one participant experienced severe hyperkalaemia (serum potassium 6.9 mmol/L; BI 690517 10 mg). UACR responses ≥20% decrease from baseline (first morning void urine) after 28 days were observed for 80.0% receiving BI 690517 40 mg (eight of 10) versus 37.5% receiving placebo (three of eight). Aldosterone levels were suppressed by BI 690517, but not eplerenone or placebo. Conclusions BI 690517 was generally well tolerated, reduced plasma aldosterone and may decrease albuminuria in participants with diabetes and albuminuric chronic kidney disease.